FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:68-72 January 2, 2003 Number 1 Next

₄ Integrins as Therapeutic Targets in Autoimmune Disease

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Miller, D. H. Related Article by Ghosh, S. PubMed Citation

In this issue of the Journal, two groups of investigators report on clinical trials of natalizumab, a recombinant monoclonal antibody against ₄ integrins, for the treatment of multiple sclerosis¹ and Crohn's disease.² Miller et al. report that a group of patients with multiple sclerosis who received monthly injections of natalizumab had significantly fewer new inflammatory central nervous system lesions than the placebo group (a reduction of approximately 90 percent) and had approximately half as many clinical relapses.¹ Ghosh et al. report that patients with Crohn's disease also had an improved response to natalizumab,² with response and remission rates that were approximately . . . [Full Text of this Article]

Source Information

From the Center for Blood Research and Department of Pathology, Harvard Medical School, Boston (U.H.A.); and the Max Planck Institute for Vascular Biology, Münster, Germany (B.E.).

This article has been cited by other articles:

• Linker, R. A., Kieseier, B. C. (2008). Review: Innovative monoclonal antibody therapies in multiple sclerosis. Therapeutic Advances in Neurological Disorders 1: 33-42 [Abstract]  
• Feral, C. C., Neels, J. G., Kummer, C., Slepak, M., Olefsky, J. M., Ginsberg, M. H. (2008). Blockade of {alpha}4 Integrin Signaling Ameliorates the Metabolic Consequences of High-Fat Diet-Induced Obesity. Diabetes 57: 1842-1851 [Abstract] [Full Text]  
• Ransohoff, R. M. (2007). Natalizumab for Multiple Sclerosis. NEJM 356: 2622-2629 [Full Text]  
• Sweet, B. V. (2007). Natalizumab update. Am J Health Syst Pharm 64: 705-716 [Abstract] [Full Text]  
• Choudry, B. A., Chan, J. W. (2007). An Update on Monoclonal Antibody Therapies in Multiple Sclerosis. Journal of Pharmacy Practice 20: 167-180 [Abstract]  
• Berger, J R (2006). Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 65: iii48-iii53 [Abstract] [Full Text]  
• Narayanan, R., Kuppermann, B. D. (2006). Uncertain Compassion in Using a Drug Before the Risks and Benefits Are Known. Arch Ophthalmol 124: 1032-1034 [Full Text]  
• Rivera-Nieves, J., Burcin, T. L., Olson, T. S., Morris, M. A., McDuffie, M., Cominelli, F., Ley, K. (2006). Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis. JEM 203: 907-917 [Abstract] [Full Text]  
• Priestley, G. V., Scott, L. M., Ulyanova, T., Papayannopoulou, T. (2006). Lack of {alpha}4 integrin expression in stem cells restricts competitive function and self-renewal activity. Blood 107: 2959-2967 [Abstract] [Full Text]  
• Keeley, K. A, Rivey, M. P, Allington, D. R (2005). Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease. The Annals of Pharmacotherapy 39: 1833-1843 [Abstract] [Full Text]  
• Danese, S., De La Rue, S. A., Gasbarrini, A., Feagan, B. G., Fox, I. H., Kishimoto, K. (2005). Antibody to {alpha}4{beta}7 Integrin for Ulcerative Colitis. NEJM 353: 1180-1181 [Full Text]  
• Kleinschmidt-DeMasters, B.K., Tyler, K. L. (2005). Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis. NEJM 353: 369-374 [Abstract] [Full Text]  
• Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., Pelletier, D. (2005). Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab. NEJM 353: 375-381 [Abstract] [Full Text]  
• Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Pare, P., McDonald, J. W.D., Dube, R., Cohen, A., Steinhart, A. H., Landau, S., Aguzzi, R. A., Fox, I. H., Vandervoort, M. K. (2005). Treatment of Ulcerative Colitis with a Humanized Antibody to the {alpha}4{beta}7 Integrin. NEJM 352: 2499-2507 [Abstract] [Full Text]  
• Rivera-Nieves, J., Olson, T., Bamias, G., Bruce, A., Solga, M., Knight, R. F., Hoang, S., Cominelli, F., Ley, K. (2005). L-Selectin, {alpha}4{beta}1, and {alpha}4{beta}7 Integrins Participate in CD4+ T Cell Recruitment to Chronically Inflamed Small Intestine. J. Immunol. 174: 2343-2352 [Abstract] [Full Text]  
• Kraft, S., Fleming, T., Billingsley, J. M., Lin, S.-Y., Jouvin, M.-H., Storz, P., Kinet, J.-P. (2005). Anti-CD63 antibodies suppress IgE-dependent allergic reactions in vitro and in vivo. JEM 201: 385-396 [Abstract] [Full Text]  
• Namazi, M R (2005). Letter to the editor. Mult Scler 11: 92-92  
• Thomas, C. W., Myhre, G. M., Tschumper, R., Sreekumar, R., Jelinek, D., McKean, D. J., Lipsky, J. J., Sandborn, W. J., Egan, L. J. (2005). Selective Inhibition of Inflammatory Gene Expression in Activated T Lymphocytes: A Mechanism of Immune Suppression by Thiopurines. J. Pharmacol. Exp. Ther. 312: 537-545 [Abstract] [Full Text]  
• Hijazi, Y., Welker, H., Dorr, A. E., Tang, J.-P., Blain, R., Renzetti, L. M., Abbas, R. (2004). Pharmacokinetics, Safety, and Tolerability of R411, a Dual {alpha}4{beta}1-{alpha}4{beta}7 Integrin Antagonist After Oral Administration at Single and Multiple Once-Daily Ascending Doses in Healthy Volunteers. J Clin Pharmacol 44: 1368-1378 [Abstract] [Full Text]  
• Deloire, M. S., Touil, T., Brochet, B., Dousset, V., Caille, J.-M., Petry, K. G (2004). Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: in vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment. Mult Scler 10: 540-548 [Abstract]  
• van Montfrans, C., Bennink, R. J., de Bruin, K., de Jonge, W., Verberne, H. J., ten Kate, F. J.W., van Deventer, S. J.H., te Velde, A. A. (2004). In Vivo Evaluation of 111In-Labeled T-Lymphocyte Homing in Experimental Colitis. JNM 45: 1759-1765 [Abstract] [Full Text]  
• Mori, Y., Shimizu, N., Dallas, M., Niewolna, M., Story, B., Williams, P. J., Mundy, G. R., Yoneda, T. (2004). Anti-{alpha}4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104: 2149-2154 [Abstract] [Full Text]  
• Gattorno, M., Gregorio, A., Ferlito, F., Gerloni, V., Parafioriti, A., Felici, E., Sala, E., Gambini, C., Picco, P., Martini, A. (2004). Synovial expression of osteopontin correlates with angiogenesis in juvenile idiopathic arthritis. Rheumatology (Oxford) 43: 1091-1096 [Abstract] [Full Text]  
• Rosenbaum, J T, Deodhar, A, Suhler, E B, Smith, J R (2004). How do you know?. Br. J. Ophthalmol. 88: 980-981 [Full Text]  
• Steinman, L. (2004). Immune Therapy for Autoimmune Diseases. Science 305: 212-216 [Abstract] [Full Text]  
• Sullivan, G. W., Lee, D. D., Ross, W. G., DiVietro, J. A., Lappas, C. M., Lawrence, M. B., Linden, J. (2004). Activation of A2A adenosine receptors inhibits expression of {alpha}4/{beta}1 integrin (very late antigen-4) on stimulated human neutrophils. J. Leukoc. Biol. 75: 127-134 [Abstract] [Full Text]  
• Zeng, W., Chen, G., Kajigaya, S., Nunez, O., Charrow, A., Billings, E. M., Young, N. S. (2004). Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood 103: 325-332 [Abstract] [Full Text]  
• Goldfinger, L. E., Han, J., Kiosses, W. B., Howe, A. K., Ginsberg, M. H. (2003). Spatial restriction of {alpha}4 integrin phosphorylation regulates lamellipodial stability and {alpha}4{beta}1-dependent cell migration. JCB 162: 731-741 [Abstract] [Full Text]  
• Steinman, L. (2003). Optic Neuritis, A New Variant of Experimental Encephalomyelitis, A Durable Model for All Seasons, Now In Its Seventieth Year. JEM 197: 1065-1071 [Full Text]  
• (2003). New Therapeutic Target for Multiple Sclerosis and Crohn's Disease. JWatch General 2003: 6-6 [Full Text]